Atossa Therapeutics, Inc. Common Stock ATOS
$2.45
+2.08%
at last close
Market Cap$23.95 million
P/E Ratio—
Div Yield—
Volume36.6K
52-Week Range
$1.70$19.35
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $20.33 (+729.9% upside)
Key Stats
- Today's Range
- $2.36 – $2.61
- 50-Day Range
- $1.92 – $2.97
- 52-Week Range
- $1.70 – $19.35
- Volume
- 37K shs
- Average Volume
- 56K shs
- Market Cap
- $23.95 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 0.89
- Price / Sales
- —
Short Interest
- Short Interest
- 15.54%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- —
- Net Income
- $-37,709,000
- Net Margin
- —
- Return on Equity
- -140.55%
- Debt-to-Equity
- —
About Atossa Therapeutics, Inc. Common Stock
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Related Stocks
Compare head-to-head: ATOS vs LLY·ATOS vs JNJ·ATOS vs ABBV·ATOS vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.